Citi raised the firm’s price target on Viking Therapeutics (VKTX) to $38 from $31 and keeps a Neutral rating on the shares following the Q2 report. The firm sees investor interest in Viking increasing into the Phase 2 VK2735 data, which is expected later in 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Advances Clinical Pipeline Amid Financial Losses
- Viking Therapeutics reports Q2 EPS (58c), consensus (44c)
- Viking Therapeutics options imply 10.2% move in share price post-earnings
- Options Volatility and Implied Earnings Moves This Week, July 21 – July 24, 2025
- Viking Therapeutics (VKTX) Q2 Earnings Cheat Sheet